Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
152
resultados
Última actualización
03/05/2025 [07:01:00]
Resultados 50 a 75 de 152
Resumen de: CN119360942A
The invention provides an ulcerative colitis intestinal microbial marker, application thereof and an ulcerative colitis detection model, and belongs to the technical field of biology and biological medicine. By analyzing the composition of the intestinal microbe markers of the ulcerative colitis patient and monitoring the change of the intestinal microbe markers of the patient, the method can guide the adjustment of the intestinal microecology of the ulcerative colitis patient, makes a personalized treatment scheme for each UC patient, recovers the normal flora of the intestinal tract of the ulcerative colitis patient, and improves the treatment effect of the ulcerative colitis. The treatment effect is improved. The ulcerative colitis detection model can more accurately identify the intestinal flora difference between ulcerative colitis patients and healthy people, the ROC curve of the ulcerative colitis detection model is close to the upper left corner, the ulcerative colitis detection model has a high true positive rate under each threshold value, the AUC value reaches 0.8106, and the ulcerative colitis detection model can be used for detecting the ulcerative colitis. The ulcerative colitis detection model has good performance when distinguishing positive and negative samples.
Resumen de: CN119331783A
The invention provides a Villonella enteritidis strain and an application of the Villonella enteritidis strain. The preservation number of the Villonella enteritidis strain is GDMCC No: 65234. The invention also provides a preparation containing the Wehonor enteritidis, a culture method and application of the Wehonor enteritidis as a labeled microorganism or a target spot in preparation of drugs for screening diseases caused by the Wehonor enteritidis. According to the present invention, the virulence gene and the pathogenicity of the Wehonor enteritidis are analyzed, such that the Wehonor enteritidis has the potential pathogenicity for aggravating the inflammatory bowel disease, and the strain provides specificity in the aspects of biological characteristics, pathogenicity and the like compared with the Wehonor micrococcus, such that the cognition of the Wehonor micrococcus in the intestinal tract is new improved, and the Wehonor micrococcus enteritidis can be used for the treatment of the inflammatory bowel disease. Moreover, a new view angle and a new direction are provided for research on the effect of the Wehonor coccus in the intestinal diseases such as IBD (Infectious Bursal Disease).
Resumen de: US2025020667A1
Embodiments of the disclosure include systems, methods, and compositions for detection of imminent onset of a symptom of a gut inflammation medical condition. The disclosure also concerns microbial biosensors that detect a marker in the gut that is predictive of onset of at least one symptom of inflammatory bowel disease (IBD), for example, and such a sensor may include a promoter sensitive to the marker that is linked to expression of a detectable readout, such as in the feces of the individual with IBD.
Resumen de: US2025020660A1
The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).
Resumen de: CN119307602A
The invention discloses application of an EphB3 gene as a biomarker in preparation of a Crohn disease detection product. According to the present invention, the expression of the EphB3 gene in the Crohn disease patient is significantly up-regulated, such that the EphB3 gene can be adopted as the Crohn disease-related biomarker, can specifically detect the Crohn disease infection, and has extremely high accuracy. Meanwhile, according to the application of a reagent for detecting EphB3 receptor expression in preparing a reagent for identifying and diagnosing the Crohn disease, the expression quantity of EphB3 in the intestinal mucosa of a patient suffering from the Crohn disease is remarkably increased compared with the expression quantity of EphB3 in the intestinal mucosa of a patient suffering from enterophthisis and a patient suffering from primary intestinal lymphoma, and the difference has statistical significance (Plt; therefore, the detection of the expression of the EphB3 can be used for differential diagnosis of Crohn's disease, intestinal tuberculosis and primary intestinal lymphoma, and has extremely high specificity and accuracy.
Resumen de: CN119291201A
The invention provides a detection kit for the expression quantity of HGFAC protein in body fluid, a construction method of an IBD detection model and application of the method in IBD auxiliary diagnosis, treatment effect monitoring and prognosis outcome prediction, belongs to the field of biological medicine, and solves the problem of how to carry out IBD auxiliary diagnosis, treatment effect monitoring and prognosis outcome prediction through body fluid biomarkers. The method comprises the following steps: inputting body fluid data obtained by the HGFAC protein expression quantity in a body fluid sample detected by the detection kit into a Logistic regression model to obtain an IBD auxiliary diagnosis model; inputting target body fluid data after conventional treatment into a Logistic regression model to obtain an IBD treatment effect monitoring and prognosis outcome prediction model; and selecting an optimal random seed number according to an AUC value of an ROC curve established by the model to obtain an optimal model, and performing k-folding cross validation on the optimal model to obtain an optimal model. According to the invention, IBD auxiliary diagnosis, treatment effect monitoring and prognosis outcome prediction are carried out through the optimal model based on the body fluid biomarkers, and clinical requirements are met.
Resumen de: CN119291196A
The invention relates to the technical field of medicinal chemistry and pharmacotherapeutics, in particular to a technology and a method for confirming toxic targets of evodiamine (EVO) and accurately evaluating hepatotoxicity of evodiamine. The method comprises the following steps: determining that EVO can be directly combined through biotin labeling, pulldown, mass spectrum combination, small molecule transfection and the like, and up-regulating liver zo-1 protein to cause liver injury, while up-regulating the intestinal tract target is a key mechanism for treating the inflammatory bowel disease by EVO. By comparing the protein levels in the liver-intestine axes of animals in different states, the fact that the down-regulation of the ZO-1 protein level in the liver-intestine axis under the inflammatory bowel disease state can partially antagonize the EVO to the up-regulation of the liver ZO-1 is found, so that the liver toxicity is reduced, and only the therapeutic activity of the EVO is retained. The discovery provides an accurate target spot for understanding an EVO toxicity mechanism, and is beneficial to realizing accurate regulation and control in drug research and development and toxicity prevention in the future; meanwhile, the drug effects and toxic mechanisms of EVO in organisms in different states are compared from the aspect of ZO-1 protein expression in the liver-intestine axis, and direct evidence is provided for the theory of combating poison with poison in to
Resumen de: WO2025008439A1
The present invention relates to a composition, comprising neuropilin-1 (NRP-1) and/or a compound that maintains or upregulates intestinal epithelial NRP-1 protein levels and promotes Hedgehog (Hh) signaling in the intestinal epithelium for use in the prevention or treatment of a disease that is associated with a weakened intestinal barrier. Furthermore, the present invention relates to an in-vitro method for the detection of a weakened intestinal barrier in a mammal, comprising the steps of providing a sample of the intestinal epithelium from a donor mammal, measuring the protein or mRNA levels of epithelial neuropilin-1 (NRP-1) in epithelium cells isolated from said sample and correlating the observed NRP-1 levels with the levels observed in control samples from healthy donors, wherein lower NRP-1 levels in the sample from the donor mammal compared to the control samples indicate the presence or predisposition of a weakened intestinal barrier in said mammal.
Resumen de: JP2025003474A
To provide apparatuses for assessment of microvascular dysfunction.SOLUTION: The invention provides methods and devices for assessment of microvascular dysfunction such as microvascular obstruction (MVO) and other dysfunctional diseases of the microvasculature of many organs, including the heart. The present subject matter provides novel devices and methods to normally diagnose, restore patency, open and preserve a flow, and limit reperfusion injury in organs and cases with microvascular dysfunction. The present subject matter provides apparatuses and methods to detect, measure and treat microvascular dysfunction in real time during scenarios such as invasive angiographic/therapeutic procedures. Such procedures include therapy for organ systems including the heart (acute myocardial infarction-primary percutaneous coronary intervention (PPCI)), brain stroke (CVA), bowel ischemia/infarction, pulmonary emboli/infarction, critical limb ischemia/infarction, renal ischemia/infarction, and others.SELECTED DRAWING: Figure 1
Resumen de: EP4487864A1
The present invention relates to a composition, comprising neuropilin-1 (NRP-1) and/or a compound that maintains or upregulates intestinal epithelial NRP-1 protein levels and promotes Hedgehog (Hh) signaling in the intestinal epithelium for use in the prevention or treatment of a disease that is associated with a weakened intestinal barrier. Furthermore, the present invention relates to an in-vitro method for the detection of a weakened intestinal barrier in a mammal, comprising the steps of providing a sample of the intestinal epithelium from a donor mammal, measuring the protein or mRNA levels of epithelial neuropilin-1 (NRP-1) in epithelium cells isolated from said sample and correlating the observed NRP-1 levels with the levels observed in control samples from healthy donors, wherein lower NRP-1 levels in the sample from the donor mammal compared to the control samples indicate the presence or predisposition of a weakened intestinal barrier in said mammal.
Resumen de: CN119235918A
The invention relates to the technical field of biomedicine, in particular to a preparation process of gold juice and application of the gold juice in modern disease treatment. The preparation process of the gold juice comprises the following steps: collecting and storing excrement; diluting and filtering; sealing in a jar; long-term curing; and digging the jar to take liquid. The invention discloses an application of Jinjiang in modern disease treatment. The application comprises the following disease treatment fields: the Jinjiang is used for treating septicopyemia; the compound is used for treating intestinal related diseases, including inflammatory bowel disease and irritable bowel syndrome; the traditional Chinese medicine composition is used for treating immune system diseases, including rheumatic arthritis and systemic lupus erythematosus; the pharmaceutical composition is used for treating metabolic syndromes including obesity, diabetes and hypertension. The preparation method disclosed by the invention achieves remarkable achievements in the aspects of a preparation process, modern medical application, pharmacological research, material component analysis, curative effect verification and the like of the traditional Chinese medicine Jinjin juice, and makes positive contributions to inheritance and development of the traditional Chinese medicine Jinjin juice.
Resumen de: CN119242783A
The invention discloses an application of PNO1 in construction of an ulcerative colitis animal model. PNO1 is applied to at least one of the following items: (1) preparing a product for diagnosing ulcerative colitis; (2) screening candidate drugs for preventing and/or treating ulcerative colitis as targets; and (3) constructing the ulcerative colitis animal model. The invention firstly finds that the PNO1 gene is positively correlated with the ulcerative colitis and can be used as a marker for diagnosing the ulcerative colitis, so that the ulcerative colitis is more accurately and quickly diagnosed, and a new therapeutic target and a new therapeutic approach are provided for treating colon cancer. The invention further constructs an ulcerative colitis animal model which can be better used for pathogenic mechanism and treatment research of ulcerative colitis and screening of colitis candidate drugs.
Resumen de: WO2025006940A2
Aspects of the disclosure relate to compositions and methods for treating one or more inflammatory bowel diseases ("IBDs"), such as ulcerative colitis ("UC") and/or Crohn's disease. Some embodiments relate to a pharmaceutical dosage form comprising a core comprising an inhibitor of a protease (e.g., a bacterial protease) and a controlled release coating applied to an exterior surface of the core. In some cases, the protease inhibitor is a gliptin or a pharmaceutically acceptable salt thereof. In some cases, the controlled release coating is configured to release the protease inhibitor in the large intestine (e.g., colon) and/or small intestine of a subject to whom the pharmaceutical dosage form is administered. Some embodiments relate to methods of treating one or more IBDs comprising delivering a therapeutically effective amount of an inhibitor of a protease (e.g., a bacterial protease) to the large intestine (e.g., colon) and/or small intestine of a subject.
Resumen de: WO2025003436A1
The present application provides an ultrasensitive colorimetric assay as well as an early biomarker for patient monitoring and medical treatment of patients suffering from a possible mitochondrial dysfunction, inflammatory bowel disease, particularly Crohn's disease. The ultrasensitive colorimetric assay measures the level of L-citrulline in a plasma or serum sample; and when the level of L-citrulline in plasma or serum decreases or falls even below 30 µmol L-citrulline, this indicates a mitochondrial cell disorder caused by a relapse or an increase in intestinal inflammation due to a flare of Crohn's disease. A method of detecting and treating the mitochondrial dysfunction is also provided.
Resumen de: CN119220678A
The invention relates to the technical field of biology, in particular to a kit related to colitis and proctitis malignant transformation, which comprises an intelligent system and a top cover, a semiconductor chilling plate is arranged at the bottom of the top cover, and a cooling fin is arranged at the top of the top cover; one side of the top cover is rotationally connected with a box body; a plurality of partition plates are fixedly connected into the box body and divide the interior of the box body into a plurality of containing cavities, and fixing assemblies are arranged on the side walls of the containing cavities. The miRNA marker related to the malignant transformation of colitis and proctitis comprises a miRNA marker body, and the miRNA marker body is one or more of miR-138-5p, miR-145-5p, miR-146a-5p, miR-150-5p, miR-146a, miR-27a, miR-29a, miR-20a and miR-21. The miRNA marker can be used for detecting the malignant transformation of colitis and proctitis. A detection agent is fixed through an elastic stretching plate and a magnet, so that the possibility that the detection agent is damaged is reduced; the interior of the kit is cooled through a semiconductor chilling plate, so that a detection agent and a detection plate can be stored for a long time; high-throughput detection of the miRNA marker is realized through the detection plate, and the detection efficiency is improved.
Resumen de: CN119223942A
本发明公开了一种磁性水凝胶包裹细菌生物传感器平台与应用，属于合成生物学及临床诊断领域。该水凝胶递送回收体系包括水凝胶包裹的全细胞生物传感器和磁性微粒，其中，所述水凝胶由海藻酸钠和氯化钙构建，所述生物传感器为感应血红素的细菌。更具体地，本发明是使用海藻酸钠水凝胶封装工程细菌YES601和磁性Fe3O4微粒形成磁性水凝胶微球，作为生物传感器递送至肠道可以感应血红素而发光，再通过磁性吸附的方式从粪便中高效回收完整微球进行检测，提高了全细胞生物传感器检测肠道出血效率以及安全性。本发明提供的水凝胶递送回收体系整体设计优化策略可以提高诊断效率和实际应用价值。
Resumen de: US2024425923A1
Described herein are systems and methods for stratifying intestinal mononuclear phagocytes (MNP) expression profiles in subjects with an inflammatory bowel disease (IBD). Further provided herein are systems and methods for determining or characterizing a Crohn's Disease (CD) subtype status in a subject having CD, selecting a treatment for a subject, or treating a subject.
Resumen de: FI20225151A1
The present invention is related to a method for determining or confirming chronic inflammatory intestinal disease or a risk thereof in a subject. The method comprises detecting the presence of keratin 7 (K7) mRNA or protein in a biological sample obtained from a subject.
Resumen de: CN119183380A
The present disclosure relates to: a method for treating IBD using digestive tract content or excreta modified with an IgA antibody, a composition, and a method for producing the same; a method for obtaining an IgA antibody that makes the flora in the digestive tract of an IBD patient sound; methods, compositions, and methods of making the same for modifying the contents or excreta of the digestive tract of an IBD patient using an IgA antibody; a method for testing a patient treated with an IBD therapeutic agent containing digestive tract contents or excreta using a diagnostic agent containing an IgA antibody; a composition; and a method for producing the composition.
Resumen de: CN119162304A
The invention discloses a Crohn disease enteric microorganism marker and application thereof and a method for constructing a Crohn disease detection model.The Crohn disease enteric microorganism marker is characterized in that enteric microorganisms related to Crohn disease are extracted from metagenome data of samples of Crohn disease patients and healthy people; the method comprises the following steps: establishing a random forest model for diagnosing the Crohn disease through the intestinal microbial marker of the Crohn disease, and evaluating to obtain a Crohn disease detection model; according to the method provided by the invention, the treatment effect can be evaluated, the treatment scheme can be adjusted in time, and a new tool is provided for prognosis evaluation of a patient; the specific intestinal microbial marker aiming at the Crohn's disease is found and applied, so that the accuracy and effectiveness of early auxiliary diagnosis, prognosis and treatment of the Crohn's disease are improved, the understanding of the Crohn's disease is deepened, and the development of microbiomics in clinical application is promoted; new biomarkers can be found easily, and new biomarkers or therapeutic targets can be found.
Resumen de: KR20240175341A
본 발명은 ATP의 검출능을 갖는 효모, ATP의 검출방법 및 ATP의 검출방법에 의한 염증성 장 질환 진단용 바이오마커에 관한 것으로, 본 발명의 반딧불이 루시페라제를 발현하는 재조합 효모를 기반으로 하는 ATP의 검출방법인 전세포 기반 센서 시스템을 활용하여 ATP를 쉽게 검출할 수 있고 이를 이용하여 비침습 적으로 염증성 장 질환(IBD)과 같은 ATP 관련 질병의 진단에 유용하게 활용할 수 있다.
Resumen de: US2024415899A1
This document discusses, among other things, receiving a plurality of donor fecal samples from a plurality of donors and storing and indexing each respective donor fecal samples using at least one characteristic of the respective donor fecal sample. In an example, the donor fecal sample can be screened and processed for subsequent use in fecal bacteriotherapy to displace pathogenic or undesired organisms in the digestive track of a patient with healthy or desirable gut microbiota.
Resumen de: WO2024256789A1
The present invention relates to an intestinal epithelium model accurately reproducing the pathophysiological mechanisms observed in vivo in the context an inflammatory condition of the intestinal barrier. The model according to the present invention comprises two compartments separated by a semi-permeable membrane. The first compartment, corresponding to the apical pole of the intestinal epithelium, comprises a coculture of Caco-2 cells differentiated into enterocytes and HT29-MTX cells differentiated into goblet cells. The second compartment, corresponding to the basolateral pole of the intestinal epithelium, comprises a culture of THP-1 monocytic cells differentiated into macrophages. The model according to the present invention is characterized in that the cells contained in the first compartment produce interleukin 6 (IL-6) at a concentration of more than 100 pg/ml and interleukin 8 (IL-8) at a concentration of more than 150 pg/ml, and the cells contained in the second compartment produce tumour necrosis factor α (TNF-α) at a concentration of more than 40 pg/ml and interleukin 1β (IL-1β) at a concentration of more than 90 pg/ml. The present invention also relates to the method for obtaining this model and also to a method for selecting candidate compounds for the treatment of inflammatory bowel diseases by verifying their ability to stop the inflammation as soon as the permeability is increased, or verifying the restoration of the permeability and of the mucus layer.
Resumen de: TW202448503A
The present disclosure generally relates to methods, and diagnostic applications, for the treatment of ulcerative colitis. More particularly the methods and diagnostic applications of the present invention relate to expression profiles of certain gene transcripts in ulcerative colitis patients and the usefulness of the expression profiles of these gene transcripts for the treatment, and/ or diagnostic use in a subgroup of patients having ulcerative colitis.
Nº publicación: CN119120778A 13/12/2024
Solicitante:
AGRICULTURAL UNIV OF HEBEI
\u6CB3\u5317\u519C\u4E1A\u5927\u5B66
Resumen de: CN119120778A
The invention relates to the technical field of virus detection, and particularly discloses a method for detecting a chicken infectious bursal disease virus based on RAA-CRISPR/Cas13a-LFD. The sequence of the upstream primer for detecting the infectious bursal disease virus is as shown in SEQ ID NO: 1, the sequence of the downstream primer is as shown in SEQ ID NO: 2, and the sequence of the specific crRNA is as shown in SEQ ID NO: 3. According to the method provided by the invention, the target gene can be effectively amplified by reacting for 40 minutes under the condition of 37 DEG C, and a test result can be judged through LFD naked eye observation; the specificity is good, and the lowest detection limit can reach 100 copies/mu L; good repeatability and stability are realized; the coincidence rate of clinical detection reaches 98.33%, and the kit can be used for clinical rapid diagnosis and prevention and control of the infectious bursal disease (IBD).
BOPI
Sede Electrónica
